Rationale and Design of JenaMACS—Acute Hemodynamic Impact of Ventricular Unloading Using the Impella CP Assist Device in Patients with Cardiogenic Shock
Authors:
- Franz HaertelFHFranz Haertel
- Karsten LenkKLKarsten Lenk
- Michael FritzenwangerMFMichael Fritzenwanger
- Ruediger PfeiferRPRuediger Pfeifer
- Marcus FranzMFMarcus Franz
- Nedim MemisevicNMNedim Memisevic
- Sylvia OttoSOSylvia Otto
- Bernward LauerBLBernward Lauer
- Oliver WeingärtnerOWOliver Weingärtner
- Daniel KretzschmarDKDaniel Kretzschmar
- Gudrun DannbergGDGudrun Dannberg
- Julian WestphalJWJulian Westphal
Open Access
- 8 August 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (15) , 4623
Abstract
Introduction: Cardiogenic shock due to myocardial infarction or heart failure entails a reduction in end organ perfusion. Patients who cannot be stabilized with inotropes and who experience increasing circulatory failure are in need of an extracorporeal mechanical support system. Today, small, percutaneously implantable cardiac assist devices are available and might be a solution to reduce mortality and complications. A temporary, ventricular, continuous flow propeller pump using magnetic levitation (Impella®) has been approved for that purpose. Methods and Study Design: JenaMACS (Jena Mechanical Assist Circulatory Support) is a monocenter, proof-of-concept study to determine whether treatment with an Impella CP® leads to improvement of hemodynamic parameters in patients with cardiogenic shock requiring extracorporeal, hemodynamic support. The primary outcomes of JenaMACS are changes in hemodynamic parameters measured by pulmonary artery catheterization and changes in echocardiographic parameters of left and right heart function before and after Impella® implantation at different support levels after 24 h of support. Secondary outcome measures are hemodynamic and echocardiographic changes over time as well as clinical endpoints such as mortality or time to hemodynamic stabilization. Further, laboratory and clinical safety endpoints including severe bleeding, stroke, neurological outcome, peripheral ischemic complications and occurrence of sepsis will be assessed. JenaMACS addresses essential questions of extracorporeal, mechanical, cardiac support with an Impella CP® device in patients with cardiogenic shock. Knowledge of the acute and subacute hemodynamic and echocardiographic effects may help to optimize therapy and improve the outcome in those patients. Conclusion: The JenaMACS study will address essential questions of extracorporeal, mechanical, cardiac support with an Impella CP® assist device in patients with cardiogenic shock. Knowledge of the acute and subacute hemodynamic and echocardiographic effects may help to optimize therapy and may improve outcome in those patients. Ethics and Dissemination: The protocol was approved by the institutional review board and ethics committee of the University Hospital of Jena. Written informed consent will be obtained from all participants of the study. The results of this study will be published in a renowned international medical journal, irrespective of the outcomes of the study. Strengths and Limitations: JenaMACS is an innovative approach to characterize the effect of additional left ventricular mechanical unloading during cardiogenic shock via a minimally invasive cardiac assist system (Impella CP®) 24 h after onset and will provide valuable data for acute interventional strategies or future prospective trials. However, JenaMACS, due to its proof-of-concept design, is limited by its single center protocol, with a small sample size and without a comparison group.Keywords
Funding Information
- Abiomed, Aachen, Germany
This publication has 19 references indexed in Scilit:
- Hemodynamics of Mechanical Circulatory SupportJACC, 2015
- Increasing venoarterial extracorporeal membrane oxygenation flow negatively affects left ventricular performance in a porcine model of cardiogenic shockJournal of Translational Medicine, 2015
- Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trialThe Lancet, 2013
- Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic ShockNew England Journal of Medicine, 2012
- Trends in Management and Outcomes of Patients With Acute Myocardial Infarction Complicated by Cardiogenic ShockJAMA, 2005
- Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shockEuropean Heart Journal, 2005
- Cardiogenic Shock Complicating Acute Myocardial InfarctionCirculation, 2003
- The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: Data from the National Registry of Myocardial Infarction 2American Heart Journal, 2001
- Cardiogenic shock complicating acute myocardial infarction—etiologies, management and outcome: a report from the SHOCK Trial RegistryJACC, 2000
- Temporal Trends in Cardiogenic Shock Complicating Acute Myocardial InfarctionNew England Journal of Medicine, 1999